SCHEMBL5230247

SCHEMBL5230247

Cn1nc(-c2ccccc2)c2c(=O)[nH]c(-c3ccc(S(=O)(=O)Cl)cc3)nc21

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
CYP1A2 P05177 2/20 0.41
HPGD P15428 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
PARP1 P09874 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TNKS O95271 1/20 0.41
GRM5 P41594 1/20 0.41
SCD O00767 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
BLM P54132 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237936 0.89 POLB (0.54) POLBCYP1A2HPGDALDH1A1CYP2C9
SCHEMBL5234610 0.85 PARP1 (0.50) POLBCYP1A2HPGDALDH1A1CYP2C9
SCHEMBL5233091 0.85 TNKS (0.50) POLBCYP1A2HPGDALDH1A1CYP2C9
SCHEMBL5229312 0.84 PDE7A (0.47) CYP1A2KDM4E
SCHEMBL5235909 0.81 HTR2B (0.42) ALDH1A1ADORA2AADORA2BADORA1
SCHEMBL1812118 0.79 PDE5A (0.41) HPGDPARP1KDM4EGRM5
SCHEMBL5753361 0.79 PDE5A (0.39) HPGDPARP1KDM4ETNKSNPSR1
SCHEMBL5233341 0.79 TNKS (0.52) ALDH1A1PARP1KDM4ETNKS
SCHEMBL5232552 0.77 HTT (0.53) POLBHPGDALDH1A1PARP1KDM4E
SCHEMBL5230233 0.76 PDE7A (0.55) HPGDALDH1A1KDM4EADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A POLB 2355/4885CYP1A2 1060/4885HPGD 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.